@

New protein biomarker article published

scioCD - Cell surface marker and Cytokine profiling

 

Characterise a certain cell type?

 

Cell composition in a certain tissue sample?

 

In-depth profiling of CD-marker expression?

 

Increase your throughput at high sensitivity levels?

You aim at high reproducibility?

 

 

Our scioCD profiling service covers 260 different proteins :

All these proteins can be analysed in parallel within a single experiment from minute sample amounts. Thereby, scioCD antibody array analysis service is ideally suited to investigate cell composition of tissues or the differentiation status of cultured cells in a highly parallel, fast and robust fashion. In addition, protein distribution in blood samples (plasma / serum) can be analysed efficiently, providing insights in the blood cell composition.

scioCD is a complete sample-to-result service for a variety of different sample types. The respective protocols were developed over a period of 15 years and are optimised towards highest possible sensitivity combined with high reproducibility (coefficients of variation below 10%).

 

 

Target
proteins       Analysis
Service       Sample
Types       Product
brochure       Contact
us

 

 

 

 

Applications

  • profiling of cell differentiation status
  • stem cell differentiation 
  • investigate soluble CD-molecules for e.g. allograft rejection
  • inflammatory response profiling
  • immuno-oncology profiling of check-point inhibitor targets
  • characterisation of tissue-isolated primary cells
  • immune-cell surface marker profiling on
    • various B-cells 
    • stimulated T-cells
    • patient derived T-cells
    • patient derived dendritic cells
  • oncology profiling for new biomarkers e.g. Leukemia
  • tumor micro-environment profiling
  • profile response to stimuli of cell lines
  • evaluate protein expression changes in silencing/overexpression  experiments
  

Advantages

  • high content - > up to 260 proteins are analysed
  • broad coverage and parallel analysis of
    • CD molecules 
    • cytokines and chemokines
    • other relevant molecules (HLAs, p53)
  • minimal sample requirements
  • native matrixes ( non-fractionated / non-depleted )
  • sensitivity as ELISA or better
  • fully immuno-based assay
  • reliable dual-colour study design
  • high reproducibility, CV < 10%
  • most proteins are covered redundantly by two or more antibodies
  • each antibody is presented in four replicates

 

 

Target list (version 1) for the scioCD protein profiling service.

Extended version 2 to follow soon ! Contact us for the updated target overview via eMail This email address is being protected from spambots. You need JavaScript enabled to view it.

 

CD Marker Gene name   CD Marker Gene name     Chemokine / Cytokine Gene name     Additional proteins Gene name
CD1a LEU6   CD50 ICAM3     GM-CSF CSF2     ANCA PRTN3
CD2 SRBC   CD52 HE5     IFN alpha IFNA1     BDNF BDNF
CD3 T3G   CD53 TSPAN25     IFN gamma IFNG     Cox1 PTGS1
CD4 LEU3   CD54 ICAM1     IL-1alpha IL1A     CYTL CYTL1
CD5 LEU1   CD55 DAF     IL-1beta IL1B     IgE FCER1A
CD6 TP120   CD56 NCAM1     IL-2 IL2     HLA I  
CD7 LEU9   CD57 B3GAT1     IL-4 IL4     HLA-ABC  
CD8 MAL   CD58 LFA3     IL-6 IL6     HLA-DP HLA-DPB1
CD9 MIC3   CD59 MIC11     IL-7 IL7     HLA-DQ  
CD10 MME   CD61 ITGB3     IL-8 CXCL8     HLA-DR  
CD11a ITGAL   CD62L SELL     IL-10 IL10     MPO MPO
CD11b ITGAM   CD62p SELP     IL-12B IL12B     NT-4 NTF4
CD11c ITGAX   CD63 TSPAN30     IL-13 IL13     NTAL LAT2
CD13 ANPEP   CD66a CEACAM1     IL-15 IL15     pan HLA-class II  
CD14     CD66b CEACAM8     IL-16 IL16     p53 TP53
CD15 FUT4   CD66c CEACAM6     IL-18 IL18     p72Syk SYK
CD16 FCGR3A   CD66d CEACAM3     IL-37 IL37     TRYG1 TPSG1
CD17     CD66e CEACAM5     LIF LIF     TSLPR CRLF2
CD18 ITGB2   CD69 CLEC2C     TNF alpha TNF     tTG TGM2
CD19 LEU12   CD70 TNFSF7     TSLP TSLP     VEGF VEGFA
CD20 MS4A1   CD71 TFRC                
CD21 CR2   CD72 Lyb-2     Eotaxin-1 CCL11        
CD22 SIGLEC2   CD79a MB1     MIP-1 alpha CCL3        
CD23 FCER2   CD80 LAB7     RANTES CCL5        
CD24     CD86 LAB72     MCP-2 CCL8        
CD25 IL2RA   CD95 FAS     MCP-3 CCL7        
CD27 TNFRSF7   CD97       MIP-4 CCL18        
CD28 TP44   CD98 SLC3A2                
CD29 ITGB1   CD99 MIC2                
CD30 TNFRSF8   CD105 ENG                
CD31 PECAM1   CD106 VCAM1                
CD33 SIGLEC3   CD116 CSF2RA                
CD34     CD117 KIT                
CD35 CR1   CD123 IL3RA                
CD36 GP3B   CD131 CSF2RB                
CD37 TSPAN26   CD137 TNFRSF9                
CD38 ADPRC 1   CD139                  
CD40 TNFRSF5   CD147 BSG                
CD41 ITGA2B   CD162 SELPLG                
CD42b GP1BA   CD177 NB1                
CD43 SPN   CD222 IGF2R                
CD44 MDU2   CD223 LAG3                
CD45 PTPRC   CD230 PRNP                
CD46 MCP   CD235a GYPA                
CD47 MER6   CD235b GYPB                
CD48 BCM1   CD253 TNFSF10                
CD49d ITGA4   CD274 PDL1                
      CD279 PD1                

 

Which sample types can be analysed ?

Within our scioCD analysis service the following samples can be analysed:

  • plasma / serum
  • fresh frozen tissue samples
  • cellular content
  • cell culture supernatant
  • cerebrospinal fluid
  • additional sample types on request

  

Sample-to-result service

Within the analysis service, we will not only carry out the microarray experiments but also support you with a suggestion for an appropriate microarray study design as well as with the sample selection process in order to address your scientific question in the optimal way. Within 3-4 weeks after receipt of your samples you will receive a customised study report including a statistical analysis.

Our analysis service includes:

  • definition of an appropriate study design
  • sample preparation
  • protein extraction
  • protein concentration measurements
  • protein quality control
  • sample labelling
  • sample purification
  • incubation of the samples on antibody microarrays
  • microarray scanning
  • raw data acquisition
  • data normalisation
  • data analysis including cluster analysis
  • statistical testing for differentially abundant proteins
  • comprehensive study report

 

Our service portfolio

scioPhospho: protein profiling and phosphorylation status

scioPhospho: protein profiling and phosphorylation status
scioPhospho combines the advantages of a robust and cost-efficient protein expression profiling using scioDiscover with information on phosphorylation status. This combination provides a comprehensive overview on signalling events and pathway activity regulation. Features 1,300 highly relevant proteins are profiled in a single assay Phosphorylation status combined with protein expression levels…
Read more
scioDiscover - Protein Profiling on expression level

scioDiscover - Protein Profiling on expression level
Knowledge about protein expression levels is of utmost importance to predict toxic effects, estimate adverse effects of drug candidates and to identify new drug targets. Sciomics has a highly optimised…
scioCD - Cell surface marker and Cytokine profiling

scioCD - Cell surface marker and Cytokine profiling
  Characterise a certain cell type?   Cell composition in a certain tissue sample?   In-depth profiling of CD-marker expression?   Increase your throughput at high sensitivity levels? You aim…
scioUbi

scioUbi
Protein & ubiquitination profiling scioUbi is a high-content protein expression and ubiquitination level analysis. With scioUbi you can analyse up to 1,000 proteins in a single assay.   Features Screen…
scioCyto : Cytokine profiling

scioCyto : Cytokine profiling
scioCyto : Cytokine profiling scioCyto is a high-content analysis service for multiplex cytokine and chemokine profiling on protein level. A great variety of samples such as plasma, tissue, cells or…

COVID-19 related activities and services

covid 19 portfolio web

News

New article | Biomarkers for canine mammary neoplasia

| Mai 2023 | New Article: Galadima et al. used the scioCD assay to analyse canine blood samples in the context of mammary neoplasia. The proteins CD20, CD45RA and CD99 were found at altered levels. The findings were validated by Western Blotting and are suggested as novel serum biomarkers.

Galadima et al. Canine Mammary Neoplasia Induces Variations in the Peripheral Blood Levels of CD20, CD45RA, and CD99 (2023) Int. J. Mol. Sci. 24(11)
New article | Microbiota influences chemotherapy in pancreatic cancer

| February 2023 | New Article: In the study Tintelnot et al. identified a microbiota-derived metabolite that has clinical implications in the treatment of pancreatic cancer. Sciomics supported the authors by a protein profiling study of tumours derived from a mouse model upon treatment with 3-IAA and Firinox.

Tintelnot et al. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Nature 615, 168-174 (2023)
New article | HAPLN1 potentiates peritoneal metastasis in pancreatic cancer

| April 2023 | New Article: Wiedmann et al. identified HAPLN1 as a prognostic marker and as a and as a driver for peritoneal metastasis in pancreatic cancer. Sciomics contributed a plasma protein profiling of a mouse model to support this exciting study.

Wiedmann L et al. HAPLN1 potentiates peritoneal metastasis in pancreatic cancer. Nature Communications 14,2354 (2023)
New article | Predicting a severe Covid-19 disease

| April 2023 | New Article: In a protein biomarker development project initiated by Sciomics, we have identified protein biomarker panels predicting development of a severe Covid.19  disease.

Hufnagel K., Fathi A. et al. Discovery and systematic assessment of early biomarkers that predict progression to severe COVID-19 disease. Communications Medicine 3,51 (2023)
New article | Prevention of Cyclosp.-A mediated anemia and peritubular loss

| June 2022 | In a study by Robert Labes et al. insights in prevention of cyclosporine mediated anemia and peritubular capillary loss were identified.

Labes, R. et al. Daprodust. prevents cyclosp.-A mediated anemia and peritubular capillary loss. Kidney International 2022 in press.

Testimonials

Dr. Matthew Wright

Chief Scientific Officer, Kinarus Therapeutics AG, Basel, Switzerland

"We are a small biotech company without our own wet labs. Sciomics recommended a UK CRO that performed cell culture experiments for our studies. Sciomics seamlessly coordinated the transfer of the biologic materials to their facility and performed the scioCD panel to characterize cell surface markers and cytokines in cell lines treated with our small molecule drug candidates. The Sciomics data were instrumental in supporting our IP protection strategy. Their advice was very helpful and they worked with us to extract the most out of the data. We are very satisfied and highly recommend the Sciomics platform and the team."

Product: scioCD

Kyriaki Barmpa

PhD Candidate, Developmental and Cellular Biology, Luxembourg Centre for Systems Biomedicine, University of Luxembourg

"By collaborating with Sciomics, we conducted a detailed analysis of the proteome of striatum organoids, uncovering significant differences that further assisted our research. Their communication was highly efficient, and the results were delivered promptly."

Product: scioPhospho

Tweets

  • over a year ago

BACK_TO_TOP